drugset / Trial / NCT07335536

The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.

NCT07335536

Recruiting 400 enrolled Diansan Su
RandomizedParallel-groupSingle-blindPrevention

Summary

Hypoxia is the most common adverse reaction during sedation outside the operating room.Exploring novel drug combinations to reduce the incidence of hypoxia during sedation in patients undergoing transvaginal oocyte retrieval procedures enhances patient safety and lowers perioperative adverse event rates. This multicenter, prospective, randomized, controlled clinical study will compare the hypoxia incidence rate of the remimazolam-alfentanil combination against the commonly used propofol-alfentanil combination.

Timeline

Start
2025-10-20
Primary completion
2026-12-20
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Propofol Small molecule 6 mg/kg
Subject Remimazolam Small molecule 1 mg/kg
Background Alfentanil Other / unclassified
Background Fentanyl Other / unclassified 7 ug/kg

Indications